IGF1R and neoplasm: In this context, our finding of upregulated p-Akt (Ser473) and p-mTOR (Ser2448) in patient 1's resistant tumor that emerged following IGF1R antibody therapy is consistent with a resistance mechanism that could be related to upregulation of TORC2.